DiaMedica Therapeutics (NASDAQ:DMAC) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

DiaMedica Therapeutics (NASDAQ:DMAC) posted its earnings results on Wednesday. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03, Zacks reports. During the same quarter in the previous year, the company earned ($0.16) earnings per share.

DiaMedica Therapeutics Price Performance

Shares of DMAC traded up $0.20 during mid-day trading on Friday, reaching $3.55. 49,032 shares of the company’s stock were exchanged, compared to its average volume of 50,152. The business’s fifty day simple moving average is $3.02 and its 200-day simple moving average is $2.92. DiaMedica Therapeutics has a 52-week low of $1.94 and a 52-week high of $3.81. The stock has a market capitalization of $151.73 million, a PE ratio of -6.34 and a beta of 1.50.

Insider Buying and Selling

In other DiaMedica Therapeutics news, major shareholder Koch Thomas Von bought 1,200,000 shares of DiaMedica Therapeutics stock in a transaction dated Friday, June 28th. The stock was acquired at an average cost of $2.50 per share, with a total value of $3,000,000.00. Following the completion of the acquisition, the insider now owns 5,526,435 shares of the company’s stock, valued at $13,816,087.50. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Separately, Craig Hallum started coverage on DiaMedica Therapeutics in a research report on Wednesday, April 24th. They set a “buy” rating and a $8.00 target price on the stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.